USPTO Examiner BOWLES DAVID PAUL - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19071109COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOFMarch 2025December 2025Allow920NoNo
19005623COMPOSITIONS COMPRISING PEMVIDUTIDE AND AN ACYLATED AMINO ACIDDecember 2024October 2025Allow911YesNo
18604387NUCLEASE-DENDRIMER FORMULATIONS FOR COVID-19 AND BROAD-SPECTRUM ANTIVIRAL THERAPY AND PROPHYLAXISMarch 2024October 2025Allow1901NoNo
18374478H-NOX PROTEINS FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONSSeptember 2023October 2025Abandon2501NoNo
18463221USE OF ANTI-AGING GLYCOPEPTIDES TO ENHANCE PANCREATIC CELL HEALTH, SURVIVAL AND IMPROVE TRANSPLANT OUTCOMESeptember 2023September 2025Allow2420NoNo
18298209ANTIMICROBIAL PEPTIDE (AMP) FOR CONTROLLING PSEUDOMONAS SYRINGAE PV. ACTINIDIAE (PSA) AND PREPARATION METHOD AND USE THEREOFApril 2023September 2025Allow2920YesNo
18177367De Novo Design of Immunoglobulin-like DomainsMarch 2023August 2025Abandon3001NoNo
18150761RECOMBINANT FACTOR VIII VARIANTSJanuary 2023August 2025Abandon3101NoNo
18064571FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAMEDecember 2022October 2025Abandon3401NoNo
18057567Targeted Therapy of Kidney FibrosisNovember 2022August 2025Abandon4301NoNo
18055255MULTIMERIC BICYCLIC PEPTIDE LIGANDSNovember 2022March 2025Allow2811YesNo
17915847EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING COVID-19September 2022January 2026Allow4010YesNo
17905010PBP3 BINDING BICYCLIC PEPTIDE LIGANDSAugust 2022January 2026Abandon4110NoNo
17820251GLP-1 AGONIST POLYPEPTIDE COMPOUND AND SALT THEREOF, SYNTHESIS METHOD THEREFOR AND USE THEREOFAugust 2022November 2025Allow3911NoNo
17757622PCSK9 ANTAGONIST COMPOUNDSJune 2022September 2025Allow3910NoNo
17785758INCRETIN ANALOGS AND USES THEREOFJune 2022May 2025Allow3500NoNo
17782935BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17June 2022November 2025Abandon4210NoNo
17781947PEPTIDES FOR THE TREATMENT OF CANCER AND/OR METASTASISJune 2022September 2025Allow3910NoNo
17827055CELL PENETRATING PEPTIDES AND USES THEREOFMay 2022November 2025Allow4221YesNo
17777917IMMUNOMODULATORSMay 2022December 2025Allow4311YesNo
17733886NUTRITIONALLY-OPTIMIZED COLLAGEN PEPTIDEApril 2022September 2025Allow4111YesNo
17769668BICYCLIC PEPTIDE LIGAND DRUG CONJUGATESApril 2022March 2026Abandon4710NoNo
17768199Proteasome InhibitorsApril 2022September 2025Abandon4101NoNo
17648560BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137January 2022March 2024Allow2620NoNo
17617670PHARMACEUTICAL PARENTERAL COMPOSITION OF DUAL GLP1/2 AGONISTDecember 2021November 2025Allow4720NoNo
17613272CYCLIC DOMINANT NEGATIVE COMPETENCE STIMULATING PEPTIDE ANALOGS AND METHODS OF TREATING STREPTOCOCCUS PNEUMONIAE INFECTIONSNovember 2021September 2025Allow4611NoNo
17444294NOVEL LINKERSAugust 2021October 2025Allow5011NoNo
17310431PHARMACEUTICAL TACI-FC FUSION PROTEIN FORMULATIONAugust 2021August 2025Allow4911NoNo
17311062LINKERSJune 2021August 2025Allow5121NoNo
17299292POLYPEPTIDE HAVING EFFECT OF INHIBITING PROLIFERATION OF LEUKEMIA CELLSJune 2021June 2025Allow4910YesNo
17186489Enhancers of Neurolysin ActivityFebruary 2021February 2025Allow4711NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner BOWLES, DAVID PAUL - Prosecution Strategy Guide

Executive Summary

Examiner BOWLES, DAVID PAUL works in Art Unit 1654 and has examined 7 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.

Allowance Patterns

Examiner BOWLES, DAVID PAUL's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BOWLES, DAVID PAUL receive 1.29 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BOWLES, DAVID PAUL is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by BOWLES, DAVID PAUL. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.